Penn Capital Management’s Pacira BioSciences PCRX Stock Holding History

Penn Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-276,378	Closed	-$12M	–	228
2019 Q2	$12M	Sell	276,378 -13,434	-5%	-$570K	1.19%	15
2019 Q1	$11M	Buy	289,812 +65,073	+29%	+$2.54M	1.07%	26
2018 Q4	$12.3M	Sell	224,739 -40,516	-15%	-$1.89M	1.22%	17
2018 Q3	$16.4M	Sell	265,255 -76,325	-22%	-$3.3M	1.25%	13
2018 Q2	$11M	Sell	341,580 -50,935	-13%	-$1.76M	0.82%	51
2018 Q1	$12.3M	Buy	392,515 +58,218	+17%	+$2.07M	0.97%	33
2017 Q4	$15.4M	Buy	334,297 +59,455	+22%	+$2.36M	1.07%	18
2017 Q3	$10.4M	Buy	274,842 +32,549	+13%	+$1.31M	0.76%	54
2017 Q2	$11.6M	Buy	242,293 +235,615	+3,528%	+$10.9M	0.86%	47
2017 Q1	$325K	Buy	+6,678	New	+$289K	0.02%	257

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Penn Capital Management's PCRX Position: Q3 2019 in Review

Penn Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2019, closing a stake of 276,378 shares — an estimated $12M sold.

Penn Capital Management first reported a position in PCRX in Q1 2017 and held it in 10 quarters. The position peaked at $16.4M in Q3 2018. 211 funds tracked by Wall St. Rank hold PCRX as of Q3 2019.

Penn Capital Management reported no remaining Pacira BioSciences position as of Q3 2019 after selling out during the quarter.
Penn Capital Management sold 276,378 Pacira BioSciences shares in Q3 2019, an estimated $12M.
Penn Capital Management first reported a position in Pacira BioSciences in Q1 2017 and held it in 10 quarters.
Penn Capital Management's Pacira BioSciences position peaked at $16.4M in Q3 2018.
211 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2019.

Based on Penn Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.